Democrats have a plan to cap insulin at $35 a month. Republicans won't say if they'll block it.
It is an open question whether Democrats will pass their Build Back Better bill this year, or ever — Sen. Joe Manchin (D-W.Va.) reiterated his ambivalence on Monday, even as he and President Biden spoke about the bill on the phone. But the version of the legislation that passed the House and is working its way through the Senate would cap insulin costs at $35 a month for people with insurance, either private or through Medicaid. Biden touted this provision of the bill last week.
"But it's a pledge Democrats may be unable to keep" to struggling diabetics, even if Manchin signs off, The Washington Post reports. "Senate Republicans are eyeing a procedural move to prevent the insulin cap from applying to privately insured Americans, seeking to deny Democrats a talking point heading into next year's midterm elections — even if it means that some patients will go without relief."
Facing lockstep GOP opposition to the expansive legislation, Senate Democrats plan to pass the bill through the budget reconciliation process. "Senate Republicans repeatedly declined to comment on whether they would use the 'Byrd rule' — which governs legislation enacted through the budget process — to knock out part of Biden's insulin plan," the Post reports. "Republicans have been meeting with the Senate parliamentarian to determine whether the bill's health provisions would technically qualify under budget reconciliation," and "if Senate Republicans challenge the insulin provision," and the parliamentarian sides with them, they "could call a point of order to strip the provision from the bill."
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Senate Republicans, and former President Donald Trump, supported lowering insulin prices that have shot up in recent years for no discernable reason. They could decide not to challenge the plan in the Build Back Better legislation. Some progressive Democrats, on the other hand, are urging Senate Democrats to expand the plan to include the uninsured.
"As I researched this topic, I found that 25 to 30 percent of Americans ration their insulin because of high cost," S. Vincent Rajkumar, a Mayo Clinic physician, tells the Post. "The ability to keep increasing the price every year on the same product happens only when there is no market force" to keep drugmakers in check. Read more at The Washington Post.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Will California’s Proposition 50 kill gerrymandering reform?Talking Points Or is opposing Trump the greater priority for voters?
-
‘The trickle of shutdowns could soon become a flood’Instant Opinion Opinion, comment and editorials of the day
-
Wikipedia: Is ‘neutrality’ still possible?Feature Wikipedia struggles to stay neutral as conservatives accuse the site of being left-leaning
-
Doctors sound the alarm about insurance company ‘downcoding’The Explainer ‘It’s blatantly disrespectful,’ one doctor said
-
Can TrumpRx really lower drug prices?Today’s Big Question Pfizer’s deal with Trump sent drugmaker stocks higher
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
Private equity firms might be causing more deaths in hospital ERsThe Explainer Deaths in ERs purchased by private equity firms rose 13%
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
The UK’s opioid crisis: why the stats don’t add upThe Explainer A new report has revealed that the UK’s total of opioid-related deaths could be much greater than official figures show
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
